CanSino Biologics Inc.’s single-dose Covid-19 vaccine – given at a lower dosage than that for adults – is safe and triggers an immune response in children aged 6-17, results from a small trial showed.

Severe Covid-19 may trick the immune system into producing so-called autoantibodies that have the potential to eventually attack healthy tissue and cause inflammatory diseases, researchers warned in a paper published in Nature Communications. Another study suggests that the virus that causes Covid-19 may be getting better at traveling into the air

Positive final results from the Phase III COSMIC-311 trial for Cabometyx (cabozantinib) were reported by Exelixis for patients diagnosed with previously treated radioactive iodine-refractory differentiated thyroid cancer.

A study on weight loss suggests that, apart from body mass index (BMI), the likelihood that a person will fail or succeed at shedding the pounds is linked to the genetic makeup of one’s gut microbiome. 

Data from Moderna Inc.’s large Covid-19 vaccine trial shows that the protection it offers wanes over time, supporting the case for booster doses, the company said in a news release on Sept. 15.

Researchers at the National Autonomous University of Mexico (UNAM) created a facemask using silver and copper nanolayers that neutralizes SARS-CoV-2, the virus that causes Covid-19, the university’s official gazette said on Aug. 26.

Llama antibodies could soon be playing a role in the global fight against Covid-19, if clinical trials being conducted by a Belgian biomedical start-up live up to their early promise.

The Feinstein Institutes for Medical Research, the research unit of New York State health care provider Northwell Health, may have found a way to control neurons that drive inflammation.

Covid-19 probably can be eradicated globally, just like polio, according to research just published in BMJ Global Health. That assumes, however, that a high rate of vaccination occurs globally and that there is a quick response to emerging variants.

Antibody levels in people inoculated with CanSino Biologics’ (CanSinoBIO) single-dose Covid-19 vaccine fell by some 30 percent after six months, however a booster shot could offer a significant lift, a senior executive said on Aug. 5.